Trial Profile
A Phase 4 Randomized, Double-blind Study Comparing Patient Comfort and Safety Between Iodixanol 320 mg I/mL and Iopamidol 370 mg I/mL in Patients Undergoing Contrast-Enhanced Computed Tomographic (CECT) Imaging of the Abdomen/Pelvis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Sep 2015
Price :
$35
*
At a glance
- Drugs Iodixanol (Primary) ; Iopamidol
- Indications Gastrointestinal disorders
- Focus Adverse reactions; Diagnostic use
- Sponsors GE Healthcare
- 02 Sep 2015 New trial record